| Name | Title | Contact Details |
|---|---|---|
David Wilson |
Senior Director of Corporate Communications, Sales and Marketing Informatics | Profile |
Shannon Jones |
Regional Director Cardiovascular Sales | Profile |
Mike Colaiacovo |
Zone Sales Director-Central | Profile |
D.M.I. Medical is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BIOPHILE Inc is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Viseon is a privately held medical device company committed to developing proprietary technology for use in Minimally Invasive Spine Surgery (MISS) procedures.
Sysmex America, Inc. distributes and supports automated `in vitro` diagnostic hematology, coagulation and urinalysis analyzers, reagents, and information systems for laboratories and healthcare facilities throughout the Western Hemisphere.? The company was formerly known as Sysmex Corporation Of America and changed its name to Sysmex America, Inc. in June 2003. The company was founded in 1979 and is based in Lincolnshire, Illinois. Sysmex America, Inc. operates as a subsidiary of Sysmex Corp.
Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment – headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2—or NMD2—ready for step two, which is accurately and objectively measuring the patient`s level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0.01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patient`s visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens—recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine—is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.